Browse > Article

Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4-substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4, 5-e] [1, 2, 4]thiadiazines  

Yan, Ren-Zhang (Institute of Medicinal Chemistry, School of Pharmacy, Shandong University)
Liu, Xin-Yong (Institute of Medicinal Chemistry, School of Pharmacy, Shandong University)
Xu, Wen-Fang (Institute of Medicinal Chemistry, School of Pharmacy, Shandong University)
Pannecouque, Christophe (Rega Institute for Medical Research, Katholieke Universiteit Leuven)
Witvrouw, Myriam (Rega Institute for Medical Research, Katholieke Universiteit Leuven)
Clercq, Erik De (Rega Institute for Medical Research, Katholieke Universiteit Leuven)
Publication Information
Archives of Pharmacal Research / v.29, no.11, 2006 , pp. 957-962 More about this Journal
Abstract
A novel series of 2-(m-Chlorobenzyl)-4-substituted-1, 1, 3-trioxo-2H, 4H-pyrazolo[4, 5-e][1, 2, 4] thiadiazines (7a-k) were synthesized, and evaluated for their anti-HIV replication in MT-4 cell cultures. Compound (7a) showed activity against HIV-1-induced cytopathicity, with an $EC_{50}$ value of $45.6\;{\mu}M$, but none of the compounds exhibited inhibitory activity against HIV-2.
Keywords
Synthesis; Pyrazolothiadiazines; HIV-1; NNRTIs; MT-4 cells;
Citations & Related Records

Times Cited By Web Of Science : 4  (Related Records In Web of Science)
Times Cited By SCOPUS : 4
연도 인용수 순위
1 Arranz M. E., Diaz, J. A., Ingate, S. T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clercq, E., and Vega, S., Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. J. Med. Chem., 41, 4109-4117 (1998)   DOI   ScienceOn
2 Arranz, M. E., Díaz, J. A., Ingate, S. T., Witvrouw, M., Pannecouque, C., Balzarini, J., De Clerq, E., and Vega, S., Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno [3,4-e] [1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem., 7, 2811-2822 (1999)   DOI   ScienceOn
3 Arranz, M. E., Díaz, J. A., Vega, S., Campos-Toimil, M., Orallo, F., Cardelus, I., Llenas, J., and Fernandez, A. G., Synthesis and pharmacological evaluation of 2, 3-dihydro-3-oxo-4Hthieno [3, 4-e][1, 2, 4]thiadiazine 1, 1-dioxidesas voltagedependent calcium channel blockers. Eur. J. Med. Chem., 35, 751-759 (2000)   DOI   ScienceOn
4 Patani, G. P. and LaVoie, E. J., Bioisosterism: A rational approach in drug design. Chem. Rev., 96, 3147-3176 (1996)   DOI   ScienceOn
5 Witvrouw, M., Arranz, M. E., Pannecouque, C., Declerq, R., Jonckheere, H., Schmit, J. C., Vandamme, A. M., Dia, J. A., Ingate, S. E., Desmyter, J., Esnouf, E., Meervelt, L. V., Vega, S., Bazarni, J., and De Clercq, E., 1,1,3-Trioxo-2H,4H-thieno [e-3,4][1,2,4]thiadiazines (TTDs) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrob. Agents. Chemother., 42, 618 -623 (1998)
6 Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq, E., Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods., 20,309- 321 (1988)   DOI   ScienceOn
7 Das, K., Lewi, P. J., Hughes, S. H., and Arnold, E., Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol., 88, 209- 231 (2005)   DOI   ScienceOn
8 Martinez, A., Gil, C., Perez, C., Castro, A., Prieto, C., Otero, J., Andrei, G., Snoeck, R., Balzarini, J., and De Clercq E., Nucleoside human cytomegalovirus inhibitors: Synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. J. Med. Chem., 43, 3267-3273 (2000b)   DOI   ScienceOn
9 Joncckheere, H., Anne, J., and De Clercq, E., The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev., 20, 129-154 (2000)   DOI   ScienceOn
10 Schaefer, W., Gunar Friebe, W., Leinert, H., Mertens, A., Poll, T., Vonder Saal, W., Zilch, H., Nuber, B., and L. Ziegler, M., Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and x-ray structure investigations. J. Med. Chem., 36, 726-732 (1993)   DOI   ScienceOn
11 De Clercq, E., Recent highlights in the development of new antiviral drugs. Curr Opin Microbiol., 8, 552-560 (2005)   DOI   ScienceOn
12 Arranz, M. E., Vega, S., and Díaz, J. A., Synthesis of Hetero [ 1,2,4]thiadiazine 1,1-Dioxides. Heterocycles, 45, 1767-1774 (1997)   DOI
13 Martinez, A., Gil, C., Abasolo, M. I., Castro, A., Bruno, A. M., Perez, C., Prieto, C., and Otero, J., Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: Synthesis and comparative molecular field analysis. J. Med. Chem., 43, 3218-3225 (2000a)   DOI   ScienceOn